A5101679937- Atrial Fibrillation Management and Outcomes
- Neonatal and Maternal Infections
- Functional Brain Connectivity Studies
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Pediatric health and respiratory diseases
- Cardiac Arrhythmias and Treatments
- Neonatal Respiratory Health Research
- Acute Ischemic Stroke Management
- Gastrointestinal motility and disorders
- Health Systems, Economic Evaluations, Quality of Life
- Breastfeeding Practices and Influences
- Probiotics and Fermented Foods
- Erythropoietin and Anemia Treatment
- Medical and Biological Ozone Research
- Blood transfusion and management
- Atherosclerosis and Cardiovascular Diseases
- Phytochemical compounds biological activities
- Ziziphus Jujuba Studies and Applications
- Bariatric Surgery and Outcomes
- Maternal and Neonatal Healthcare
- Pharmacological Effects and Toxicity Studies
- Spondyloarthritis Studies and Treatments
- Ginkgo biloba and Cashew Applications
- Phase Change Materials Research
Shanghai Tenth People's Hospital
2019-2024
Tongji University
2019-2024
Guangxi Normal University
2024
Chengdu University of Traditional Chinese Medicine
2024
University of Liverpool
2022
Liverpool Heart and Chest Hospital
2022
Shihezi University
2021
Shandong Provincial Hospital
2011-2013
Third Hospital of Changsha
2013
Shandong University
2011
Background Current management of patients with atrial fibrillation (AF) is limited by low detection AF, non-adherence to guidelines and lack consideration patient's preferences, thus highlighting the need for a holistic integrated approach AF management. This study aims determine whether mHealth technology-supported strategy will reduce AF-related adverse events. Methods/design The mAFA II trial prospective, cluster randomised controlled trial. 40 sites be mAFA-integrated care intervention...
Abstract Background The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) randomised trial demonstrated the efficacy of a mobile health (mHealth) technology-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway-approach (mAFA intervention) reducing risk adverse events patients with atrial (AF). Whether these benefits also apply to older is unclear. In this ancillary analysis, we evaluated effect mAFA intervention among patients. Methods...
To investigate the impact of Small Intestinal Bacterial Overgrowth (SIBO) on efficacy Fecal Microbiota Transplantation (FMT) in patients with chronic constipation, our research team included 218 constipation treated FMT. Based results SIBO breath test, were divided into two groups: group and without (non-SIBO). The groups was evaluated using constipation-related scoring scales. At same time, feces small intestinal fluid samples collected from both before after FMT to compare changes...
<title>Abstract</title> Objectives The Systemic Immune-inflammatory Index (SII), an emergent biomarker for inflammation, has recently garnered attention. Psoriasis, characterized by its immune-inflammatory nature, presents intriguing domain exploring potential associations with SII. This investigation is poised to unravel the complexities of this relationship. Methods Leveraging data from National Health and Nutrition Examination Survey (NHANES), spanning five distinct cycles (2003–2004,...
Six new triterpenoids, heritieras C-H (
Fecal microbiota transplantation (FMT) is a therapy that involves the of healthy human fecal microorganisms into gut patients to rebuild or consolidate intestinal microecology. It has been utilized in many diseases. However, FMT had limited effect on with small diseases because unique ecological characteristics microorganisms. Thus, we proposed new microecology called fluid (HIFT). Human can be collected through nasojejunal tube and made capsules using freeze-dried powder method. In...
<h3>Objectives</h3> To study the effects of Bushenhuoxue Granules on sleep quality patients with parkinson’s disease. <h3>Methods</h3> Totally 96 were enrolled and randomly divided into two groups, control group treated placebo treatment Granules, both based Madopar treatment. A multi-centre, randomised, placebo-controlled, double-blind clinical was adopted in period. And follow-up period for 6 months, Parkinson’s disease scale (PDSS) to measure PD at baseline time, after 3 9 months....